Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease
Substrate reduction therapy (SRT) has been proposed as a new gene therapy for Fabry disease (FD) to prevent the formation of globotriaosylceramide (Gb3). Nanomedicines containing different siRNA targeted to Gb3 synthase (Gb3S) were designed. Formulation factors, such as the composition, solid lipid...
Saved in:
Main Authors: | Marina Beraza-Millor (Author), Julen Rodríguez-Castejón (Author), Jonatan Miranda (Author), Ana del Pozo-Rodríguez (Author), Alicia Rodríguez-Gascón (Author), María Ángeles Solinís (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice
by: Julen Rodríguez-Castejón, et al.
Published: (2021) -
mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation
by: Itziar Gómez-Aguado, et al.
Published: (2021) -
Ribonucleic acid interference induced gene knockdown
by: Sruthima N. V. S. Gottumukkala, et al.
Published: (2013) -
Topical Administration of SLN-Based Gene Therapy for the Treatment of Corneal Inflammation by De Novo IL-10 Production
by: Mónica Vicente-Pascual, et al.
Published: (2020) -
The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials
by: Alicia Rodríguez-Gascón, et al.
Published: (2021)